[1]
|
Wei, X., Li, N., Li, S., et al. (2017) Hepatitis B Virus Infection and Active Replication Promote the Formation of Vascu-lar Invasion in Hepatocellular Carcinoma. BMC Cancer, 17, Article No. 304.
https://doi.org/10.1186/s12885-017-3293-6
|
[2]
|
Qu, C., Huang, X., Liu, K., et al. (2019) Effect of Hepatitis B Vi-rus DNA Replication Level and Anti-HBV Therapy on Microvascular Invasion of Hepatocellular Carcinoma. Infectious Agents and Cancer, 14, Article No. 2.
https://doi.org/10.1186/s13027-019-0219-8
|
[3]
|
Yang, F., Ma, L., Yang, Y., et al. (2019) Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Frontiers in Oncology, 9, Article No. 370.
https://doi.org/10.3389/fonc.2019.00370
|
[4]
|
Lei, Z., Li, J., Wu, D., et al. (2016) Nomogram for Preoperative Es-timation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma within the Milan Criteria. JAMA Surgery, 151, Article No. 356.
https://doi.org/10.1001/jamasurg.2015.4257
|
[5]
|
Li, Z., Lei, Z., Xia, Y., et al. (2018) Association of Preoperative Antiviral Treatment with Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surgery, 153, e182721.
https://doi.org/10.1001/jamasurg.2018.2721
|
[6]
|
Wang, Z., Duan, Y., Zhang, J., et al. (2020) Preoperative Antivi-ral Therapy and Microvascular Invasion in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis. Eu-ropean Journal of Pharmacology, 883, Article ID: 173382.
https://doi.org/10.1016/j.ejphar.2020.173382
|
[7]
|
Sanaka, S., Kasarala, G.R. and Tillmann, H.L. (2018) A Down-side to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression. The Journal of Infectious Diseases, 217, 857-860. https://doi.org/10.1093/infdis/jix659
|
[8]
|
Dave, S., Park, S., Murad, M.H., et al. (2021) Comparative Effectiveness of Entecavir versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A System-atic Review and Meta-Analysis. Hepatology, 73, 68-78. https://doi.org/10.1002/hep.31267
|
[9]
|
Galle, P.R., Forner, A., Llovet, J.M., et al. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. https://doi.org/10.1016/j.jhep.2018.03.019
|
[10]
|
Heimbach, J.K., Kulik, L.M., Finn, R.S., et al. (2018) AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 67, 358-380. https://doi.org/10.1002/hep.29086
|
[11]
|
Benson, A.B., D’Angelica, M.I., Abrams, T.A., et al. (2014) Hepatobiliary Cancers, Version 2.2021. Journal of the National Comprehensive Cancer Network, 12, 1152. https://doi.org/10.6004/jnccn.2014.0112
|
[12]
|
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版) [J]. 临床肝胆病杂志, 2022, 38(2): 288-303.
|
[13]
|
Li, C., Wang, M.D., Lu, L., et al. (2019) Preoperative Transcatheter Arte-rial Chemoembolization for Surgical Resection of Huge Hepatocellular Carcinoma (≥10 cm): A Multicenter Propensity Matching Analysis. Hepatology International, 13, 736-747. https://doi.org/10.1007/s12072-019-09981-0
|
[14]
|
Zhou, Q., Tuo, F., Li, R., et al. (2020) Transarterial Chemoem-bolization Combined with Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Frontiers in Oncology, 10, Article ID: 578763.
https://doi.org/10.3389/fonc.2020.578763
|
[15]
|
Guo, C., Zou, X., Hong, Z., et al. (2021) Preoperative Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Score Matching Analysis. HPB, 23, 1427-1438. https://doi.org/10.1016/j.hpb.2021.02.006
|
[16]
|
Zhou, Y., Zhang, X., Wu, L., et al. (2013) Meta-Analysis: Preoperative Transcatheter Arterial Chemoembolization Does Not Improve Prognosis of Patients with Resectable Hepatocellular Carcinoma. BMC Gastroenterology, 13, Article No. 51. https://doi.org/10.1186/1471-230X-13-51
|
[17]
|
Yang, Y., Lin, K., Liu, L., et al. (2021) Impact of Preoperative TACE on Incidences of Microvascular Invasion and Long-Term Post-Hepatectomy Survival in Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis. Cancer Medicine, 10, 2100-2111. https://doi.org/10.1002/cam4.3814
|
[18]
|
Shin, S.W., Ahn, K.S., Kim, S.W., et al. (2021) Liver Resection versus Local Ablation Therapies for Hepatocellular Carcinoma within the Milan Criteria: A Systematic Review and Me-ta-Analysis. Annals of Surgery, 273, 656-666.
https://doi.org/10.1097/SLA.0000000000004350
|
[19]
|
Imai, K., Yamashita, Y.I., Yusa, T., et al. (2018) Microvas-cular Invasion in Small-Sized Hepatocellular Carcinoma: Significance for Outcomes Following Hepatectomy and Radiof-requency Ablation. Anticancer Research, 38, 1053-1060.
|
[20]
|
Lee, S., Kang, T.W., Song, K.D., et al. (2021) Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma after Surgery and Radiofrequency Abla-tion. Annals of Surgery, 273, 564-571.
https://doi.org/10.1097/SLA.0000000000003268
|
[21]
|
Jung, D.H., Hwang, S., Lee, Y.J., et al. (2019) Small Hepatocellular Carcinoma with Low Tumor Marker Expression Benefits More from Anatomical Resection than Tumors with Aggressive Biology. Annals of Surgery, 269, 511-519.
https://doi.org/10.1097/SLA.0000000000002486
|
[22]
|
Hwang, S., Lee, Y.J., Kim, K.H., et al. (2015) The Impact of Tumor Size on Long-Term Survival Outcomes after Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. Journal of Gastrointestinal Surgery, 19, 1281-1290.
|
[23]
|
Ke, Q., Guo, Z., He, J., et al. (2023) Resection Margin Width Does Not Influence the Prognosis of Solitary Hepatocellular Carcinoma after Anatomic Resection: A Real-World Study from China. Journal of Hepatocellular Carcinoma, 10, 1353-1365. https://doi.org/10.2147/JHC.S420828
|
[24]
|
Poon, R.T.P., Fan, S.T., Ng, I.O.L., et al. (2000) Significance of Resec-tion Margin in Hepatectomy for Hepatocellular Carcinoma: A Critical Reappraisal. Annals of Surgery, 231, 544-551.
https://doi.org/10.1097/00000658-200004000-00014
|
[25]
|
Shi, M., Guo, R.P., Lin, X.J., et al. (2007) Partial Hepa-tectomy with Wide versus Narrow Resection Margin for Solitary Hepatocellular Carcinoma: A Prospective Randomized Trial. Annals of Surgery, 245, 36-43.
https://doi.org/10.1097/01.sla.0000231758.07868.71
|
[26]
|
Zhong, F.P., Zhang, Y.J., Liu, Y. and Zou, S.B. (2017) Prognostic Impact of Surgical Margin in Patients with Hepatocellular Carcinoma: A Meta-Analysis. Medicine (Baltimore), 96, e8043.
https://doi.org/10.1097/MD.0000000000008043
|
[27]
|
Tsilimigras, D.I., Sahara, K., Moris, D., et al. (2020) Effect of Surgical Margin Width on Patterns of Recurrence among Patients Undergoing R0 Hepatectomy for T1 Hepatocellular Carcinoma: An International Multi-Institutional Analysis. Journal of Gastrointestinal Surgery, 24, 1552-1560. https://doi.org/10.1007/s11605-019-04275-0
|
[28]
|
Wang, H., Yu, H., Qian, Y.W., Cao, Z.Y., Wu, M.C. and Cong, W.M. (2020) Impact of Surgical Margin on the Prognosis of Early Hepatocellular Carcinoma (≤ 5 cm): A Propensity Score Matching Analysis. Frontiers in Medicine (Lausanne), 7, Article No. 139. https://doi.org/10.3389/fmed.2020.00139
|
[29]
|
Yang, P., Si, A., Yang, J., et al. (2019) A Wide-Margin Liver Re-section Improves Long-Term Outcomes for Patients with HBV-Related Hepatocellular Carcinoma with Microvascular Invasion. Surgery, 165, 721-730.
https://doi.org/10.1016/j.surg.2018.09.016
|
[30]
|
Han, J., Li, Z.L., Xing, H., et al. (2019) The Impact of Resection Margin and Microvascular Invasion on Long-Term Prognosis after Curative Resection of Hepatocellular Carcinoma: A Multi-Institutional Study. HPB (Oxford), 21, 962-971.
https://doi.org/10.1016/j.hpb.2018.11.005
|
[31]
|
Sun, J.J., Wang, K., Zhang, C.Z., et al. (2016) Postoperative Adju-vant Transcatheter Arterial Chemoembolization after R0 Hepatectomy Improves Outcomes of Patients Who Have Hepa-tocellular Carcinoma with Microvascular Invasion. Annals of Surgical Oncology, 23, 1344-1351. https://doi.org/10.1245/s10434-015-5008-z
|
[32]
|
Ye, J.Z., Chen, J.Z., Li, Z.H., et al. (2017) Efficacy of Postopera-tive Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients with Microvascular Inva-sion. World Journal of Gastroenterology, 23, 7415-7424.
https://doi.org/10.3748/wjg.v23.i41.7415
|
[33]
|
Chen, Z.H., Zhang, X.P., Zhou, T.F., et al. (2019) Adjuvant Transarterial Chemoembolization Improves Survival Outcomes in Hepatocellular Carcinoma with Microvascular Invasion: A Systematic Review and Meta-Analysis. European Journal of Surgical Oncology, 45, 2188-2196. https://doi.org/10.1016/j.ejso.2019.06.031
|
[34]
|
Wang, L., Chen, B., Li, Z., et al. (2019) Optimal Postoperative Ad-juvant Treatment Strategy for HBV-Related Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis. OncoTargets and Therapy, 12, 1237-1247.
https://doi.org/10.2147/OTT.S179247
|
[35]
|
Wang, L., Wang, W., Rong, W., et al. (2020) Postoperative Adjuvant Treatment Strategy for Hepatocellular Carcinoma with Microvascular Invasion: A Non-Randomized Interventional Clini-cal Study. BMC Cancer, 20, Article No. 614.
https://doi.org/10.1186/s12885-020-07087-7
|
[36]
|
Yang, J., Liang, H., Hu, K., et al. (2021) The Effects of Several Postoperative Adjuvant Therapies for Hepatocellular Carcinoma Patients with Microvascular Invasion after Curative Re-section: A Systematic Review and Meta-Analysis. Cancer Cell International, 21, Article No. 92. https://doi.org/10.1186/s12935-021-01790-6
|
[37]
|
Bruix, J., Takayama, T., Mazzaferro, V., et al. (2015) Adjuvant Sorafenib for Hepatocellular Carcinoma after Resection or Ablation (STORM): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 16, 1344-1354.
https://doi.org/10.1016/S1470-2045(15)00198-9
|
[38]
|
Huang, Y., Zhang, Z., Zhou, Y., Yang, J., Hu, K. and Wang, Z. (2019) Should We Apply Sorafenib in Hepatocellular Carcinoma Patients with Microvascular Invasion after Curative Hepatectomy? OncoTargets and Therapy, 12, 541-548.
https://doi.org/10.2147/OTT.S187357
|
[39]
|
Zhang, X.P., Chai, Z.T., Gao, Y.Z., et al. (2019) Postoperative Adju-vant Sorafenib Improves Survival Outcomes in Hepatocellular Carcinoma Patients with Microvascular Invasion after R0 Liver Resection: A Propensity Score Matching Analysis. HPB, 21, 1687-1696. https://doi.org/10.1016/j.hpb.2019.04.014
|
[40]
|
Gu, W. and Tong, Z. (2020) Sorafenib in the Treatment of Patients with Hepatocellular Carcinoma (HCC) and Microvascular Infiltration: A Systematic Review and Meta-Analysis. Journal of International Medical Research, 48, 1-10.
https://doi.org/10.1177/0300060520946872
|